Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Inclusion Criteria: * Patients with newly diagnosed stage I (T\>1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy * The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in ≤ 10% of invasive cancer cells by Immunohistochemistry. * HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing * No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer * Female subjects age 18 - 70 years * ECOG Performance Status of 0-1 * Adequate organ and marrow function as defined below: * Leukocytes ≥ 3,000/uL * Absolute neutrophil count ≥ 1500/uL * Platelets ≥ 100,000/uL * Total bilirubin ≤ 1.5mg/dL * AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal * Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min * Serum albumin ≥ 3.0 g/dL * Women of child-bearing potential must agree to use adequate contraception * Pretreatment lab values must be performed within 14 days of treatment initiation, and other baseline studies performed within 30 days prior to registration * Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4 weeks prior to treatment initiation * Subjects should have breast and axillary imaging with breast MRI or breast and axillary ultrasound within 4 weeks prior to treatment initiation * Subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy/fine needle aspiration. * Subjects must be already enrolled in P.R.O.G.E.C.T observational registry * Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease * Subjects with bilateral disease are eligible if they meet other eligibility criteria. * Neuropathy: No baseline neuropathy grade \> 2 Exclusion Criteria: * Current or anticipated use of other investigational agents * Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer * Subject with metastatic disease * History of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study * Subjects with inflammatory breast cancer * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements * Subject is pregnant or nursing * Subjects with concomitant or previous malignancies within the last 5 years. Exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS). * Ejection Fraction \<50% on ECHO or MUGA * Cardiac function: Subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP\>160 or Diastolic BP\>90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral vascular disease